What is the BPC-157 + TB-500 + KPV stack? It is a three-component peptide combination encountered in research and commercial listings, containing BPC-157, TB-500 and KPV. The combination does not have a universally standardized composition, and the complete three-peptide combination has not been established as a clinically validated formulation.
The name describes a combination of three distinct research peptides: BPC-157, TB-500 and KPV. It should be understood as a market or research combination, not as the name of a single molecule, established drug, or universally standardized clinical formulation.
Unlike a recognized pharmaceutical formulation, the naming of multi-peptide research combinations is inconsistent. Current market documentation has used labels including Coremend and Wolverine Plus, but these names do not reliably define one universal composition.
| Name / description | Classification | What to understand |
|---|---|---|
| BPC-157 + TB-500 + KPV | Descriptive | Directly identifies the three components without assuming a branded formulation. |
| Coremend | Market name | Used in current commercial documentation for a BPC-157/TB-500/KPV combination, but the name itself does not create a regulatory standard. |
| Wolverine Plus | Community / commercial name | The term is not sufficiently standardized to determine contents without checking the actual formulation. |
| Wolverine | Community name | Commonly associated with BPC-157 + TB-500, but naming conventions vary between vendors. |
Each ingredient has its own research record. The following cards describe the research context of each component without treating that evidence as proof of the combined stack.
BPC-157 is a synthetic 15-amino-acid peptide extensively studied in preclinical models involving tissue injury, inflammation and musculoskeletal repair.
Human evidence remains limited. Recent reviews describe only a small number of pilot or observational human studies and emphasize the lack of robust randomized clinical evidence.
Mostly preclinical evidenceTB-500 is generally used to describe a synthetic fragment related to thymosin beta-4. This distinction is important because human clinical research involving full-length thymosin beta-4 should not automatically be attributed to the TB-500 fragment.
FDA materials state that human exposure data for TB-500 drug products have not been identified.
Fragment ≠ full-length Tβ4KPV is the C-terminal tripeptide sequence of alpha-melanocyte- stimulating hormone. Laboratory and animal research has investigated anti-inflammatory signaling, including intestinal inflammatory models.
However, the presence of mechanistic and animal evidence does not establish clinical efficacy of KPV in humans.
Preclinical / translational evidencePreclinical literature includes animal models examining tissue repair, angiogenesis, inflammation and musculoskeletal injury. Human evidence is substantially smaller and lacks the controlled clinical evidence needed to establish efficacy.
Evidence tier: Preclinical dominantFull-length thymosin beta-4 has been evaluated in human clinical research, including wound-healing studies. Those findings cannot be directly transferred to TB-500, which refers to a different fragment.
Evidence tier: Full-length Tβ4 has human data; TB-500 fragment lacks established clinical evidenceKPV has been studied in cell and animal models of inflammatory processes, including experimental intestinal inflammation. These studies provide biological evidence for further research rather than proof of clinical effectiveness.
Evidence tier: Preclinical dominantThe available evidence does not establish that BPC-157 + TB-500 + KPV as a complete combination has been tested in a controlled human clinical trial.
Therefore, claims that the three compounds are synergistic, additive, superior to individual compounds, or clinically effective as a stack should be treated as hypotheses rather than established clinical conclusions.
| Evidence category | Status | What it means |
|---|---|---|
| BPC-157 alone | Preclinical + limited human research | Provides a separate evidence base for BPC-157 only. |
| TB-500 alone | Limited / no established human evidence | Must not be equated with the human literature on full-length thymosin beta-4. |
| KPV alone | Predominantly preclinical | Experimental inflammatory findings do not establish human treatment efficacy. |
| BPC-157 + TB-500 + KPV | Combination evidence gap | No controlled clinical evidence identified for the complete combination. |
There is no pharmacopeial or universally accepted formulation for this three-component stack. Current market documentation includes a 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV example. Because other sources use different names and compositions, this should be treated as a documented market example rather than a universal formulation.
| Component | Illustrative documented formulation | Mass share | Standardized? |
|---|---|---|---|
| BPC-157 | 10 mg | 33.33% | No |
| TB-500 | 10 mg | 33.33% | No |
| KPV | 10 mg | 33.33% | No |
| Total | 30 mg | 100% | No universal standard |
For a multi-component vial, adding more liquid increases the final volume while the amount of each peptide remains unchanged. Therefore, every component's concentration decreases according to the same mathematical relationship, but each component must still be calculated from its own mass.
Component concentration = component mass ÷ final liquid volumeThe following table uses the illustrative 10 mg + 10 mg + 10 mg formulation solely to demonstrate the mathematics.
| Component | Vial mass | 1 mL | 2 mL | 3 mL | 5 mL |
|---|---|---|---|---|---|
| BPC-157 | 10 mg | 10 mg/mL | 5 mg/mL | 3.333 mg/mL | 2 mg/mL |
| TB-500 | 10 mg | 10 mg/mL | 5 mg/mL | 3.333 mg/mL | 2 mg/mL |
| KPV | 10 mg | 10 mg/mL | 5 mg/mL | 3.333 mg/mL | 2 mg/mL |
For example, 30 mg total peptide in 5 mL does equal 6 mg/mL as a mathematical total peptide mass concentration. But that does not mean BPC-157 is 6 mg/mL, TB-500 is 6 mg/mL, or KPV is 6 mg/mL.
In the equal-mass 10/10/10 example, each individual peptide is 2 mg/mL at a 5 mL final volume.
The mathematical relationship is inverse: if the peptide mass stays constant while the final liquid volume increases, the concentration decreases proportionally.
| Final volume | BPC-157 | TB-500 | KPV | Total peptide concentration* |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 10 mg/mL | 10 mg/mL | 30 mg/mL |
| 2 mL | 5 mg/mL | 5 mg/mL | 5 mg/mL | 15 mg/mL |
| 3 mL | 3.333 mg/mL | 3.333 mg/mL | 3.333 mg/mL | 10 mg/mL |
| 5 mL | 2 mg/mL | 2 mg/mL | 2 mg/mL | 6 mg/mL |
*Total peptide concentration is the mathematical sum of the three individual mass concentrations. It should not be substituted for an individual component concentration.
Use the BacScience Universal BAC Water Calculator for single-compound concentration calculations. For a multi-component vial, enter or verify each component independently because every ingredient retains its own mass.
Open the BAC Water CalculatorThe rationale for combining these compounds is primarily based on the idea that they may affect different biological processes. BPC-157 is investigated extensively in preclinical tissue-repair models, TB-500 is marketed around the biology associated with thymosin beta-4 fragments, and KPV has been studied for anti-inflammatory activity.
| Component | Research concept | What the evidence does NOT establish |
|---|---|---|
| BPC-157 | Tissue-response, vascular and inflammatory research. | That adding BPC-157 improves outcomes when combined with TB-500 and KPV. |
| TB-500 | Fragment-related tissue and cell-migration research. | That human findings involving full-length thymosin beta-4 apply directly to TB-500. |
| KPV | Anti-inflammatory cellular and animal research. | That preclinical anti-inflammatory activity translates into clinical efficacy of the complete stack. |
| Question | Evidence status |
|---|---|
| Has BPC-157 been researched? | Yes, extensively in preclinical models; human evidence remains limited. |
| Has thymosin beta-4 been researched in humans? | Yes, including clinical wound-healing research involving full-length Tβ4. |
| Does that prove TB-500 efficacy? | No. TB-500 is a distinct fragment and should not be treated as identical to full-length Tβ4. |
| Has KPV been researched? | Yes, predominantly through laboratory and animal inflammatory research. |
| Has BPC-157 + TB-500 + KPV been clinically tested? | No controlled combination study identified. |
| Does individual evidence prove stack efficacy? | No. Combination efficacy requires combination-specific evidence. |
BPC-157, KPV and TB-500 should not be presented on this page as established FDA-approved therapies.
FDA materials identify BPC-157, KPV and thymosin beta-4 fragment (TB-500) among substances for which important safety and/or pharmaceutical-quality information is limited. For TB-500 specifically, FDA states that it has not identified human exposure data for drug products containing the fragment.
These limitations include questions surrounding peptide-related impurities, immunogenicity, aggregation and adequate characterization.
Full-length thymosin beta-4 is a 43-amino-acid endogenous peptide that has been evaluated in human research. TB-500 is commonly used to refer to a shorter synthetic fragment. Results from studies involving the full protein therefore should not automatically be presented as clinical evidence for TB-500.
It is a three-component peptide combination containing BPC-157, TB-500 and KPV. The combination is encountered in research and commercial contexts but is not an established standardized clinical formulation.
No. Different commercial names and formulations can contain different components or amounts. The actual vial composition should always be checked directly.
No controlled clinical study evaluating the complete BPC-157 + TB-500 + KPV combination was identified.
No. BPC-157 research describes BPC-157 itself. It does not establish the efficacy or safety of BPC-157 when combined with TB-500 and KPV.
No. TB-500 commonly refers to a synthetic fragment associated with thymosin beta-4. Full-length thymosin beta-4 is a different molecule. Clinical evidence for full-length thymosin beta-4 should not be represented as direct clinical evidence for TB-500.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Laboratory and animal research has examined its anti-inflammatory properties.
Divide the mass of that specific component by the final liquid volume. For example, 10 mg of BPC-157 in 5 mL gives 2 mg/mL BPC-157. Perform the same calculation independently for TB-500 and KPV.
You can calculate total peptide mass concentration mathematically, but you must not use the combined mass as the concentration of each individual peptide.
Mathematically, adding more liquid does not change the stated mass of each peptide. It changes the concentration because the same mass is distributed through a larger final volume.
No. The concentration calculations are mathematical research references and should not be interpreted as dosing recommendations or clinical instructions.
| Anchor text | Recommended destination | Purpose |
|---|---|---|
| BAC Water Calculator | /pages/bac-water-calculator | Concentration calculation tool |
| BPC-157 Research | /pages/bpc-157-research | Individual component evidence |
| TB-500 Research | /pages/tb-500-research | Fragment-specific evidence |
| KPV Research | /pages/kpv-research | Individual KPV evidence |
| Peptide Reconstitution Research | /pages/peptide-reconstitution | General mathematical reference |
Last reviewed: September 11, 2026. This page is an educational research reference and is not a substitute for medical advice, prescribing information, or regulatory guidance.